An update on the safety of current therapies for Alzheimer's disease: focus on rivastigmine [0.03%]
当前阿尔茨海默病主要疗法的安全性分析：以石杉碱甲为例
Rita Khoury,Jayashree Rajamanickam,George T Grossberg
Rita Khoury
Alzheimer's disease (AD) is the most common cause of major neurocognitive disorders worldwide. Despite all research efforts, therapeutic options for AD are still limited to two drug classes: cholinesterase inhibitors (ChEIs) and the NMDA-re...
Can supporting health literacy reduce medication-related harm in older adults? [0.03%]
提高健康素养能否减少老年人的药物相关伤害？
Nikesh Parekh,Khalid Ali,Kevin Davies et al.
Nikesh Parekh et al.
Polypills for the secondary prevention of cardiovascular disease: effective in improving adherence but are they safe? [0.03%]
用于二级预防心血管病的复方药：提高依従性但安全吗？
Vanessa Selak,Ruth Webster
Vanessa Selak
International guidelines recommend blood pressure-lowering therapy, statins and aspirin for people who have had a cardiovascular event but use of these medications is low, particularly for lower income countries. Clinical trials have demons...
Interventions to reduce medication errors in neonatal care: a systematic review [0.03%]
减少新生儿护理中用药错误的干预措施：系统评价研究
Minh-Nha Rhylie Nguyen,Cassandra Mosel,Luke E Grzeskowiak
Minh-Nha Rhylie Nguyen
Background: Medication errors represent a significant but often preventable cause of morbidity and mortality in neonates. The objective of this systematic review was to determine the effectiveness of interventions to redu...
Influence of stroke and bleeding risk on prescribing of oral anticoagulants in older inpatients; has the availability of direct oral anticoagulants changed prescribing? [0.03%]
口服抗凝药的开具受卒中和出血风险的影响；直接口服抗凝药的可用性改变了药物处方吗？
Nicholas Farinola,Gillian E Caughey,J Simon Bell et al.
Nicholas Farinola et al.
Background: Little is known about changes in prescribing practices in Australia since the introduction of the direct oral anticoagulants (DOACs). Our objective was to examine if the availability of DOACs has coincided wit...
Contemporary utilization of antithrombotic therapy for stroke prevention in patients with atrial fibrillation: an audit in an Australian hospital setting [0.03%]
澳大利亚医院针对房颤患者卒中预防的抗栓治疗现状调查分析
Ekta Yogeshkumar Pandya,Elizabeth Anderson,Clara Chow et al.
Ekta Yogeshkumar Pandya et al.
Background: To document antithrombotic utilization in patients with nonvalvular atrial fibrillation (NVAF), particularly, recently approved NOACs (nonvitamin K antagonist oral anticoagulants) and warfarin; and identify fa...
Severe haematuria of lower urinary tract origin with low dose dabigatran use in three Indian elderly patients: unresolved issues in the safety of novel oral anticoagulants [0.03%]
印度3名老年患者轻度使用达比加群导致下尿路严重血尿：新型口服抗凝药安全性问题未解决
Upinder Kaur,Sankha Shubhra Chakrabarti,Sukdev Manna et al.
Upinder Kaur et al.
Dabigatran is a newer oral direct thrombin inhibitor approved by the United States Food and Drug Administration and the European Medicines Agency (EMA). The proper dosage of the drug, the potential for adverse drug reactions and the nature ...
Naloxone dosage for opioid reversal: current evidence and clinical implications [0.03%]
阿片类药物逆转的纳洛酮剂量：现有证据及临床意义
Rachael Rzasa Lynn,J L Galinkin
Rachael Rzasa Lynn
Opioid-related mortality is a growing problem in the United States, and in 2015 there were over 33,000 opioid-related deaths. To combat this mortality trend, naloxone is increasingly being utilized in a pre-hospital setting by emergency per...
Precision medicine: does ethnicity information complement genotype-based prescribing decisions? [0.03%]
精确医学：族裔信息能补充基于基因型的用药决策吗？
Rashmi R Shah,Andrea Gaedigk
Rashmi R Shah
Inter-ethnic differences in drug response are all too well known. These are underpinned by a number of factors, including pharmacogenetic differences across various ethnic populations. Precision medicine relies on genotype-based prescribing...
Doron Garfinkel
Doron Garfinkel
Background: The aim of this study was to evaluate efficacy and safety of poly-de-prescribing (PDP) based on the Garfinkel method in older people with polypharmacy. ...